Title |
A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial
|
---|---|
Published in |
Trials, July 2013
|
DOI | 10.1186/1745-6215-14-237 |
Pubmed ID | |
Authors |
Mark A Hull, Anna C Sandell, Alan A Montgomery, Richard FA Logan, Gayle M Clifford, Colin J Rees, Paul M Loadman, Diane Whitham |
Abstract |
The naturally-occurring omega (omega)-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid (EPA) reduces colorectal adenoma (polyp) number and size in patients with familial adenomatous polyposis. The safety profile and potential cardiovascular benefits associated with omega-3 PUFAs make EPA a strong candidate for colorectal cancer (CRC) chemoprevention, alone or in combination with aspirin, which itself has recognized anti-CRC activity. Colorectal adenoma number and size are recognized as biomarkers of future CRC risk and are established as surrogate end-points in CRC chemoprevention trials. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 112 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 18 | 16% |
Student > Master | 15 | 13% |
Student > Ph. D. Student | 14 | 13% |
Student > Bachelor | 11 | 10% |
Student > Doctoral Student | 7 | 6% |
Other | 22 | 20% |
Unknown | 25 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 42 | 38% |
Nursing and Health Professions | 10 | 9% |
Agricultural and Biological Sciences | 9 | 8% |
Biochemistry, Genetics and Molecular Biology | 8 | 7% |
Neuroscience | 2 | 2% |
Other | 12 | 11% |
Unknown | 29 | 26% |